Immunologic Agents : Immunomodulators
IBETA1 “Betaferon injection” 0.3 mg/vial
適應症：降低反覆發作型多發性硬化症的發作頻率及嚴重度。降低續發型多發性硬化症(secondary progressive multiple sclerosis)復發的頻率及嚴重度。發生單一臨床症狀(Clinically Isolated Syndrome)疑似多發性硬化症的病患，可延緩其惡化成多發性硬化症。
Usual dose:
Multiple sclerosis, Relapsing forms: SC, 0.25 mg qod; usual dose is reached after a 6-wk, gradual titration with initial dose of 0.0625 mg SC qod increased by 25% every 1-2 wks.
Adverse effect:
Common: injection site pain, local skin reaction – finding, sweating symptom, asthenia, headache, influenza-like illness, fever, chills, myalgia.
Serious: hypertension, palpitations, tachyarrhythmia, injection site necrosis, leukopenia, increased liver aminotransferase level, anaphylaxis, depression, mental disorder.
Related Entries
(Visited 35 times, 1 visits today)